Supernus Pharmaceuticals, Inc.

SUPN Nasdaq SEC CIK 1356576
Follow Supernus Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $226.8M +18% vs same quarter last year
Net income $20.9M +146.4% vs same quarter last year
EPS, diluted $0.35 +143.8% vs same quarter last year
Operating cash flow $6.6M +110.7% vs same quarter last year
Revenue by quarter
$174.2M
$149.8M
$165.5M
$192.1M
$211.6M
$207.7M
$219.1M
$226.8M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$250M$0$250M$500M$750MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$719M−$38.6M
FY24$661.8M$73.9M
FY23$607.5M$1.3M
FY22$667.2M$60.7M
FY21$579.8M$53.4M
FY20$520.4M$127M
FY19$392.8M$113.1M
FY18$408.9M$111M
FY17$302.2M$57.3M
FY16$215M$91.2M
FY15$147.5M$13.9M
FY14$92.7M−$10.9M
FY13$12M−$92.3M
FY12$1.5M−$46.3M
FY11$803K$53.8M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−5000%0%5000%10000%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2589.6%−8.7%−5.4%
FY2488.2%12.3%11.2%
FY2386.2%−0.9%0.2%
FY2286.9%6.9%9.1%
FY21-14.8%9.2%
FY2089.9%33.4%24.4%
FY1995.8%37.8%28.8%
FY1896.2%35.3%27.1%
FY1795%32.9%19%
FY1694.4%25.2%42.4%
FY1594.3%14.1%9.5%
FY1493.8%−5.7%−11.8%
FY1390.8%−515.2%−767.7%
FY12-−2849.3%−3127.3%
FY11-−4701.4%6701.7%
Free cash flowOperating cash flow minus capital expenditure
−$100M$0$100M$200MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25$46M
FY24$171.2M
FY23$110.5M
FY22$116.4M
FY21-
FY20$135M
FY19$140.4M
FY18$128.1M
FY17$112.6M
FY16$65.2M
FY15$32.4M
FY14−$25.1M
FY13−$59.6M
FY12−$48M
FY11−$36.9M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Supernus Pharmaceuticals
  • Healthcare median
−5000%−2500%0%2500%5000%7500%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearSupernus PharmaceuticalsHealthcare median
FY25−5.4%−30.6%
FY2411.2%−47%
FY230.2%−58%
FY229.1%−80.4%
FY219.2%−71.8%
FY2024.4%−62.2%
FY1928.8%−46.2%
FY1827.1%−49.6%
FY1719%−45.9%
FY1642.4%−36%
FY159.5%−37.8%
FY14−11.8%−35.5%
FY13−767.7%−37.1%
FY12−3127.3%−29.1%
FY116701.7%−27.9%